High Resolution Optical Coherence Tomography
- Conditions
- Retinal DiseaseRetinal DetachmentRetinal DystrophyRetinal Vein OcclusionRetinal Artery OcclusionRetinal EdemaDiabetic Macular EdemaMacular DiseaseHypertensive RetinopathyUveitis
- Interventions
- Device: High-resolution optical coherence tomography (High-Res-OCT)Device: Standard spectral domain OCT (SD-OCT)
- Registration Number
- NCT05130385
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Brief Summary
Comparison of high-resolution optical coherence tomography (High-Res-OCT) to conventional imaging modalities for the diagnosis of eye diseases
- Detailed Description
The high resolution optical coherence tomography (High-Res-OCT) is an improvement of a non-invasive routinely used imaging technique, the optical coherence tomography (OCT), with a light-source capable of providing an increased axial resolution. The routinely used Spectral-Domain OCT has a center wavelength of 880 nm and a spectral bandwidth of 40 nm, resulting in an axial resolution of approximately 7 μm in the eye and is used routinely worldwide. The High-Res OCT works with a central wavelength of 840 nm and an increased bandwidth of 130 nm, making it possible to improve the optical axial resolution in tissue from 7 to 3 µm, without increasing the maximum laser exposure limit. The improved axial resolution of the High-Res OCT results in clearer and more detailed images. The technique is routinely used in clinical practice and the device used for High-Res-OCT (Heidelberg, SPECTRALIS® High-Res OCT- DMR001) has received CE mark (european conformity in the extended Single Market in the European Economic Area) approval in March 2021. We plan to compare High-Res-OCT as an imaging modality to conventional imaging modalities used in clinical routine, such as the Spectral-Domain-OCT (SD-OCT)
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 550
- Patients from the Department of Ophthalmology, University Hospital Bern requiring conventional imaging for eye disease and willing to sign informed consent Patients of 18 years or older
- Patients not willing or able to sign informed consent
- Patients younger than 18 years
- Patients with epilepsy.
- Vulnerable subjects (except the objectives of the investigation concern vulnerable subjects specifically),
- Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject
- Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation
- Enrolment of the PI, his/her family members, employees and other dependent persons
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Diabetic Retinopathy High-resolution optical coherence tomography (High-Res-OCT) Patients with various degree of diabetic retinopathy Age related macular degeneration Standard spectral domain OCT (SD-OCT) Patients with history of age related macular degeneration Retinal changes from arterial hypertension Standard spectral domain OCT (SD-OCT) Patients with history of arterial hypertension Healthy High-resolution optical coherence tomography (High-Res-OCT) Healthy age matched control subjects Healthy Standard spectral domain OCT (SD-OCT) Healthy age matched control subjects Artery and vein occlusion Standard spectral domain OCT (SD-OCT) Patients with history of artery or vein occlusion (central or branch artery) Artery and vein occlusion High-resolution optical coherence tomography (High-Res-OCT) Patients with history of artery or vein occlusion (central or branch artery) Optic nerve neuropathy Standard spectral domain OCT (SD-OCT) Patients with history of various optic nerve neuropathies Hereditary retinal diseases High-resolution optical coherence tomography (High-Res-OCT) Patients with history of various retinal dystrophies Retinal detachment High-resolution optical coherence tomography (High-Res-OCT) Patients history of retinal detachment Retinal detachment Standard spectral domain OCT (SD-OCT) Patients history of retinal detachment Age related macular degeneration High-resolution optical coherence tomography (High-Res-OCT) Patients with history of age related macular degeneration Uveitis Standard spectral domain OCT (SD-OCT) Patients with history of uveitis intermedia and/or posterior and/or pan-uveitis Glaucoma Standard spectral domain OCT (SD-OCT) Patients with history of glaucoma (open-angle glaucoma, chronic angle closure glaucoma) Optic nerve neuropathy High-resolution optical coherence tomography (High-Res-OCT) Patients with history of various optic nerve neuropathies Glaucoma High-resolution optical coherence tomography (High-Res-OCT) Patients with history of glaucoma (open-angle glaucoma, chronic angle closure glaucoma) Hereditary retinal diseases Standard spectral domain OCT (SD-OCT) Patients with history of various retinal dystrophies Diabetic Retinopathy Standard spectral domain OCT (SD-OCT) Patients with various degree of diabetic retinopathy Retinal changes from arterial hypertension High-resolution optical coherence tomography (High-Res-OCT) Patients with history of arterial hypertension Uveitis High-resolution optical coherence tomography (High-Res-OCT) Patients with history of uveitis intermedia and/or posterior and/or pan-uveitis
- Primary Outcome Measures
Name Time Method Evaluation of the sensitivity and specificity of High-Res-OCT for retinal fluid 2 years The primary objective of this observational study is to evaluate the sensitivity and specificity to diagnose retinal morphological abnormalities with High-Resolution OCT compared to conventional imaging method (SD-OCT). The main parameter that will be assessed is the presence/absence of retinal fluid. The incidence (binary) of retinal fluid will be assessed in High-Resolution OCT and compared to conventional imaging method, such as standard-OCT (SD-OCT)
- Secondary Outcome Measures
Name Time Method Evaluation of the sensitivity and specificity of High-Res-OCT for atrophy area 2 years The incidence (binary) of atrophy area, defined as hypertransmission due to loss of outer retinal layers within the choroidea, will be assessed in High-Resolution OCT and compared to conventional imaging method, such as standard-OCT (SD-OCT)
Evaluation of the sensitivity and specificity of High-Res-OCT for optic disc swelling 2 years The incidence (binary) of optic disc swelling will be assessed in High-Resolution OCT and compared to conventional imaging method, such as standard-OCT (SD-OCT). Optic disc swelling is defined as an elevation of the whole nerve head, measured as follows: max. horizontal extent in micrometer of the RNFL (3 mm diameter peripapillary).
Evaluation of the sensitivity and specificity of High-Res-OCT for drusen 2 years The incidence (binary) of drusen will be assessed in High-Resolution OCT and compared to conventional imaging method, such as standard-OCT (SD-OCT). Drusen are defined as hyperfluorescent deposits between the RPE and Bruch's membrane (BM). May be "hard" (small hyperreflective deposits in the retina) and "soft" (larger with indistinct edges).
Evaluation of the sensitivity and specificity of High-Res-OCT for scars 2 years The incidence (binary) of scars will be assessed in High-Resolution OCT and compared to conventional imaging method, such as standard-OCT (SD-OCT). Scars are defined as hyperreflective fibrous tissue, which obscures RPE and choroid.
Evaluation of the inter-reader reproducibility 2 years Evaluation of the inter-reader reproducibility of the diagnosis of retinal diseases with High-Res-OCT. Inter-reader reproducibility will be estimated using the Bland-Altman method and the coefficient of repeatability (CoR).
Evaluation of the sensitivity and specificity of High-Res-OCT for hyperreflective foci 2 years The incidence (binary) of hyperreflective foci will be assessed in High-Resolution OCT and compared to conventional imaging method, such as standard-OCT (SD-OCT). Hyperreflective foci are defined as intraretinal hyperreflective dots.
Subgroup analysis 2 years Subgroup analysis will be performed with patients suffering from diabetic retinopathy, artery and vein occlusion, retinal detachment, glaucoma, optic nerve neuropathy, hereditary retinal diseases, age related macular degeneration, retinal changes from arterial hypertension and uveitis. For this purpose, the presence/absence of each above-mentioned morphological abnormality will be assessed/measured in each subgroup and compared with the standard OCT.
Evaluation of the segmentation quality of the retinal layers using High-Res-OCT 2 years For this purpose the discrimination capacity between the different retinal layers will be assessed, i.e. internal limiting membrane, retinal nerve fiber layer, ganglion cell layer, inner plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, external limiting membrane, photoreceptor layers, retinal pigment epithelium, Bruch's membrane, choriocapillaris, choroidal stroma. For this purpose, a binary outcome will also result, which means that the ability to discriminate between the above-mentioned adjacent layers will be indicated by yes/no.
Evaluation of the sensitivity and specificity of High-Res-OCT for epiretinal membrane 2 years The incidence (binary) of epiretinal membrane (defined as thickening of the retinal nerve fiber layer) will be assessed in High-Resolution OCT and compared to conventional imaging method, such as standard-OCT (SD-OCT)
Evaluation of the sensitivity and specificity of High-Res-OCT for ischemia 2 years The incidence (binary) of ischemia will be assessed in High-Resolution OCT and compared to conventional imaging method, such as standard-OCT (SD-OCT). Ischemia is defined as hyperreflective band located within/above the outer plexiform layer.
Evaluation of the sensitivity and specificity of High-Res-OCT for neovascularisation 2 years The incidence (binary) of neovascularisation will be assessed in High-Resolution OCT and compared to conventional imaging method, such as standard-OCT (SD-OCT). Neovascularisation is defined as abnormal growth of vessels from the choroid to the retina through the BM.
Trial Locations
- Locations (1)
Department of Ophthalmology, Bern University Hospital, Bern, 3010 Bern, Switzerland
🇨🇭Bern 3010, Bern, Switzerland